Anticancer
Pimicotinib’s Phase III data in tenosynovial giant cell tumor are better than its rivals but the fight for a small number of patients will be fierce.
Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.
Panels at the recent BioFuture conference focused on the next breakthroughs in areas such as oncology and neurodegenerative diseases, continuing challenges to GLP-1 agonists, financing and how use of AI is taking shape.
The UK group began more clinical trials last year than any other company, a new report from Citeline has found.
Troubled GlycoMimetics will merge with Crescent, bringing its PD-1- and VEGF-targeting bispecific CR-001 and gaining a public listing. Crescent also will raise $200m to help position itself against PD-1xVEGF leaders Akeso/Summit and BioNTech.
The Swiss giant has raised its forecast for the full financial year, as Cosentyx, Entresto and its oncology portfolio continue to shine, helped by the firm's sleeker selling organization.
Lyell believes ImmPACT’s dual CD19/20-targeted CAR-T could offer better response rates than Yescarta or Breyanzi and will focus on IMPT-314 while terminating much of its own pipeline.
Biostar plans to raise up to $41m through a Hong Kong IPO, which help the Chinese chemotherapy specialist progress lead asset utidelone for various oncology indications.
Although from a small Phase I/Ib study, Arcus presents data showing better response rate, disease control and tolerability for casdatifan compared to Merck’s approved renal cell carcinoma drug Welireg.
The new company, Rhine Pharma, hopes to avoid the isotope production issues that have dogged other radiopharmaceutical developers.
The deal, potentially worth more than $1.3bn, includes Modifi’s MGMT-targeting technology, which it hopes can provide a biomarker-based approach for glioblastoma multiforme.
Positive data on its anti-TIGIT antibody belrestotug meant ITeos provided one of the biggest stories at ESMO this year. CEO Michel Detheux told Scrip there was much more to come from the US-headquartered biotech founded in Belgium.
An exec said the company is confident it can ensure testing for the biomarker becomes routine for the drug, which is the first FDA-approved medicine to target CLDN18.2.
The company and partner OncoC4 remain tight-lipped on what’s behind the partial hold in the NSCLC study of gotistobart, which could impact BioNTech’s nascent oncology plans.
The action, taken in consultation with the US FDA, follows the failure of the TROPiCS-04 study, which was the confirmatory trial for the urothelial cancer accelerated approval.
Sanofi and Orano Med have kicked off a joint venture worth $1.9bn to develop alpha-emitting cancer therapies, underscoring the importance of this space to big pharma.
CEO Nicolas Poirier talked to Scrip about the development plans for two late-stage assets: a therapeutic cancer vaccine and an IL-7 antagonist for ulcerative colitis.
Axcynsis is developing a derivative of the chemotherapy agent Yondelis as a new payload, which the Singapore venture will first apply to a Claudin 6-targeting ADC it plans to take into a Phase I trial in the US, its chairman, CEO and founder tells Scrip in an interview.
The Swiss company is aiming to regain its innovator status and expand its offering across all breast cancer settings. Approval of Itovebi is just the start.
Recent major developments in the Korean biotech sector include Orum Therapeutics’ IPO plan and HLB’s US resubmission for the approval of rivoceranib in combination with camrelizumab for first-line liver cancer.